# Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors

> **NCT06177405** · — · COMPLETED · sponsor: **Institute of Biomedical Chemistry, Russia** · enrollment: 50 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors

## Key facts

- **NCT ID:** NCT06177405
- **Lead sponsor:** Institute of Biomedical Chemistry, Russia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-15
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06177405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06177405, "Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06177405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*